A non-pyrogenic preparation containing nanoparticles synthesized by magnetotactic bacteria for medical or cosmetic applications. The nanoparticles are constituted by a crystallized mineral central part including predominantly an iron oxide, as well as a surrounding coating without material from the magnetotactic bacteria.

A non-pyrogenic preparation containing nanoparticles synthesized by magnetotactic bacteria for medical or cosmetic applications. The nanoparticles are constituted by a crystallized mineral central part including predominantly an iron oxide, as well as a surrounding coating without material from the magnetotactic bacteria.

A polymer-metal oxide complex, comprising a metal oxide particle located at the core and a polymer modified on the surface of the metal oxide particle, the polymer being provided with functional groups capable of bonding with a metal in the metal oxide, the density of the binding sites of the polymer and the surface of the metal oxide particle being greater than two sites/square nanometer. Also disclosed are a preparation method for the polymer-metal oxide complex, and applications of the polymer-metal oxide complex as a nuclear magnetic resonance contrast agent and as an iron supplement. The polymer-metal oxide complex has a significantly extended in vivo circulation time and effectively overcomes the defect that existing contrast agents cause hypersensitivity, which in addition to the superparamagnetic and iron metabolism participation functions of the complex, enables the complex to be applied as a magnetic resonance imaging contrast agent and as an iron supplement treating iron-deficiency anaemia.

Biocompatible polymeric nanoparticles may include: a biocompatible polymer and/or functional metal nanostructures. The biocompatible polymer may be a polyhydroxyalkanoate (PHA). The functional metal nanostructures may include at least one noble metal, at least one magnetic metal oxide, or mixtures thereof. The biocompatible polymeric nanoparticles may have an average size less than or equal to 200 nanometers (nm).

Disclosed are a targeting aptamer for atherosclerosis and a preparation method and application thereof. The targeting aptamer is a targeting aptamer fragment for atherosclerosis obtained through screening of macrophage-derived foam cells together with reverse screening of smooth muscle cells, endothelial cells, and THP-1 cells using a SELEX method; and the use of the targeting aptamer in preparation of an MRI targeting nano-contrast agent for atherosclerosis allows the specific binding of the MRI targeting nano-contrast agent for atherosclerosis only with the macrophage-derived foam cells, and allows high specific binding thereof with vascular tissues with AS lesion, this improving targeting effect of the MRI targeting nano-contrast agent for atherosclerosis and realizing early specific diagnosis of arterial sclerosis.

Deuterated polymer-biomolecule conjugates and the synthesis and use of deuterated polymer-biomolecule conjugates for detecting the location of specific molecules, e.g., cell surface molecules, in a subject, and for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.

The present invention relates to a biocompatible particle comprising nanoparticles of iron oxide embedded in a polycathecolamine or polyserotonine matrix, a suspension of said particles, a process for preparing said suspension of particles, a conjugate comprising said particle and the use of said particle and said conjugate in imaging techniques.

Provided herein are MRI agent-loaded platelets, methods of preparing MRI agent-loaded platelets, and methods of using MRI agent-loaded platelets. In some embodiments, methods of loading MRI agents into platelets include contacting platelets with an MRI agent, a cell penetrating peptide, and a loading buffer that can include a salt, a base, a loading agent, and optionally at least one organic solvent.

The present invention provides nanoparticles including a metallic core having a length along each axis of from 1 to 100 nanometers and a coating disposed on at least part of the surface of the metallic core, wherein the coating comprises polydopamine, along with methods for making and using such nanoparticles. The metallic core may be gold, silver or iron oxide and the polydopamine coating may have other substances bound to it, such as silver, targeting ligands or antibodies, or other therapeutic or imaging contrast agents. The disclosed nanoparticles can be targeted to cells for treating cancer or bacterial infections, and for use in diagnostic imaging.

The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core.